This trial is active, not recruiting.

Condition rabies
Treatments cv8102, rabipur, cv8102 + rabipur
Phase phase 1
Sponsor CureVac AG
Start date September 2014
End date August 2016
Trial size 72 participants
Trial identifier NCT02238756, 2013-004514-18, CV-8102-201


The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose prevention
Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
(Active Comparator)
Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
cv8102 + rabipur
Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart

Primary Outcomes

Number of subjects with serious and non serious adverse events
time frame: Up to 12 months

Secondary Outcomes

Maximum tolerated dose (MTD) of CV8102 within the dose range of 25 µg to 250 µg.
time frame: Up to day 49
MTD of CV8102 in combination with rabies vaccine
time frame: Up to Day 49
Vaccination-elicited serum rabies VNTs among the dose groups
time frame: Up to day 35
Vaccination-elicited innate and adaptive immune responses
time frame: Up to Day 35

Eligibility Criteria

Male participants from 18 years up to 40 years old.

Inclusion Criteria: 1. Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial 2. Physical examination and laboratory results without clinically significant findings 3. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 4. Subjects must use reliable forms of contraception (barrier method with spermicidal agent or true abstinence) and must refrain from sperm donation during treatment and the 4-week F/U period after the last treatment. Exclusion Criteria: 1. Use of any investigational or non-registered product (adjuvant, drug) other than CV8102 within 4 weeks preceding the administration of the CV8102, or planned use of any such agent during the trial period 2. Subject has received any licensed or non-licensed vaccines within 4 weeks prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine or planned vaccinations during the trial period 3. Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine. The use of inhaled and nasal steroids, as well as topical steroids outside the vaccination area, will be permitted 4. Any medically diagnosed or suspected immune deficient condition based on medical history and physical examination 5. History of autoimmune disease or suspected autoimmune disease based on medical history and physical examination that cannot be ruled out based on further examinations 6. Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of CV8102 or licensed rabies vaccine 7. Acute disease at the time of enrolment. Acute disease is defined as the presence of any acute condition including but not limited to non-febrile or febrile common colds, urinary tract infections, inflammatory, allergic or traumatic conditions that may interfere with safety assessment of the investigational products 8. Presence or evidence of significant acute or chronic disease, in particular heart disease including coronary artery disease and chronic pulmonary diseases (e.g., chronic obstructive pulmonary disease [COPD]); uncontrolled medical or psychiatric illness (subjects with uncomplicated chronic diagnoses stable and treated for ≥ 3 months e.g., mild hypertension well-controlled with medication, may be enrolled - provided the condition and its therapy are known not to be associated with an immunocompromised state or an autoimmune disease) 9. Major congenital defects 10. Known allergy to any component (or closely related substance) of the licensed rabies vaccine product 11. Known type I allergy to beta-lactam antibiotics 12. Evidence of current alcohol or drug abuse 13. History of any neurological disorders or seizures 14. Known seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (except in subjects previously vaccinated against HBV) or hepatitis C virus (HCV) 15. Foreseeable non-compliance with protocol as judged by the Investigator 16. History of any life-threatening anaphylactic reactions 17. Subjects with impaired coagulation in whom an IM injection is contraindicated. Additional exclusion criteria for subjects participating in the (adjuvanted) rabies vaccination part: 18. Subject has previously received any investigational or licensed rabies vaccine 19. Intending to travel to regions/countries for which rabies vaccinations are recommended or where high risk of infection exists according to travel recommendations by the German Society of Tropical Medicine and International Health (DTG) during the trial and F/U period 20. Subject is taking chloroquine for malaria treatment or prophylaxis.

Additional Information

Official title Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults
Principal investigator Ingo Meyer, MD
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by CureVac AG.